RCT Glargine vs NPH for Treatment of DM in Pregnancy

Launched by LOYOLA UNIVERSITY · Sep 26, 2024

Keywords

ClinConnect Summary

This clinical trial is studying two types of insulin, Glargine and NPH, to see which one works better for managing diabetes during pregnancy. If you are pregnant and have been diagnosed with Type 2 diabetes or gestational diabetes that requires insulin treatment, you may be eligible to participate. To join, you need to be at least 18 years old, start insulin before 34 weeks of pregnancy, and have established prenatal care by 14 weeks.

If you take part in this study, you will be randomly assigned to receive either Glargine or NPH insulin. The goal is to find out which insulin helps manage blood sugar levels more effectively and safely during pregnancy. It's important to note that this study is currently recruiting participants, and if you have any allergies to insulin, are under 18, or are managing your diabetes with diet or oral medications, you won’t be able to participate. Your involvement could help improve diabetes care for pregnant women in the future!

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Patient requiring initiation of insulin therapy for Gestational Diabetes Mellitus or Type 2 Diabetes Mellitus in pregnancy
• • At least 18 years old
• • Insulin started prior to 34 weeks gestation
• • Established prenatal care by 14 weeks gestation
• Exclusion Criteria:
• • Those under the age of 18 years old
• • Those unable to consent in english
• • Allergy to insulin
• • Controlled with only diet modification or the use of oral antihyperglycemics
• • Has diagnosis of Type 1 Diabetes Mellitus
• • Receiving insulin through an insulin pump